Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
German High-Grade Non-Hodgkin's Lymphoma Study Group |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00400907 |
RATIONALE: Treatment for diffuse large B-cell non-Hodgkin's lymphoma may cause side effects and secondary cancers later in life. An observational study that evaluates patients after undergoing six courses of combination chemotherapy with or without rituximab and radiation therapy may help doctors predict a patient's response to this treatment and help plan the best treatment.
PURPOSE: This observational study is evaluating patients with diffuse large B-cell non-Hodgkin's lymphoma to see how well treatment on clinical trial CAN-NCIC-LY9 works.
Condition | Intervention |
---|---|
Long-Term Effects Secondary to Cancer Therapy in Adults Lymphoma |
Procedure: management of therapy complications Procedure: observation |
Study Type: | Observational |
Official Title: | Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT] |
Estimated Enrollment: | 667 |
Study Start Date: | January 2006 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients successfully completing treatment on protocol CAN-NCIC-LY9 are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 667 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Study ID Numbers: | CDR0000514350, DSHNHL-MINT-FU, EU-20656, DSHNHL-M39045 |
Study First Received: | November 16, 2006 |
Last Updated: | May 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00400907 History of Changes |
Health Authority: | United States: Federal Government |
long-term effects secondary to cancer therapy in adults stage I adult diffuse large cell lymphoma contiguous stage II adult diffuse large cell lymphoma |
noncontiguous stage II adult diffuse large cell lymphoma stage III adult diffuse large cell lymphoma stage IV adult diffuse large cell lymphoma |
Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Rituximab Lymphoma, B-Cell Lymphoma, Small Cleaved-cell, Diffuse Lymphatic Diseases Antibodies |
B-cell Lymphomas Neoplasm Metastasis Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma, Large-cell Lymphoma Immunoglobulins |
Lymphoma, B-Cell Lymphatic Diseases Neoplastic Processes Neoplasms Pathologic Processes Immunoproliferative Disorders |
Neoplasms by Histologic Type Immune System Diseases Neoplasm Metastasis Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |